At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 35 enrolled
Drug / intervention
Lurasidone +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Lurasidone Effects on Tissue Glutamate in Schizophrenia
University of Texas Southwestern Medical Center·interventional·Posted Jul 24, 2014·Updated Mar 1, 2021
In Brief
A Phase 4 clinical trial evaluating Lurasidone, Haloperidol, and 1 other intervention for Schizophrenia and Schizoaffective Disorder. Completed, enrolled 35 participants across 1 site.
Detailed Summary
24 individuals with schizophrenia or schizoaffective disorders, who are currently considered stable, will be recruited, screened for entry criteria into a blinded study with a 4-week randomization to either lurasidone, haloperidol, or perphenazine to examine glutamate-related outcomes with lurasidone as compared to haloperidol and perphenazine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia, Schizoaffective Disorder
CountriesUnited States
CollaboratorsSumitomo Pharma America, Inc.
Timeline
Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2013
First PostedJul 2014
Primary CompletionJun 2016
TodayJul 2026
First PostedJul 24, 2014
Enrollment StartFeb 1, 2013
Primary CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 11.9 years ago
Interventions
Lurasidonedrug
Compare to haloperidol and perphenazine
Haloperidoldrug
Compare to lurasidone
Perphenazinedrug
Compare to lurasidone